Sergey Kozhukhov

Dr. Sergey Kozhukhov

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 August 2023 in Hellenic Journal of Cardiology
Verified
Journal Article
Open access
Sergey KozhukhovSergey Kozhukhov
Sergey Kozhukhov
APAlexander Parkhomenko
Alexander Parkhomenko
YLYaroslav Lutay
Yaroslav Lutay
NDNataliia Dovganych
Nataliia Dovganych
Myocardial infarction (MI) is one of the leading causes of death in the world. Early myocardial reperfusion improves acute MI survival. Bioflavonoid quercetin is known to have antioxidant, anti-inflammatory, and anti-proliferative properties. The presented pilot study aims to investigate the cardioprotective effect of quercetin on infarct size limiting in ST-segment elevation myocardial infarction (STEMI) patients. Patients (n=143) with the first anterior STEMI within 6 hours from symptoms onset were included in the open-label multicenter pilot study. Patients were randomized either to quercetin group (n=70) in addition to standard treatment or recommended therapy alone (control group, n=73). Quercetin infusions were initiated before reperfusion and repeated during the next 5 days. The infarct size assessed by CK-MB AUC was the primary study outcome. The study arms matched well regarding demographics, time to admission, and main clinical data. The median early CK-MB AUC was significantly lower in quercetin group than in controls (8036±7594 vs 11219±8146 U×1h/L, p=0.015). Intravenous quercetin was associated with less reperfusion-induced intramyocardial hemorrhage by Cardiac Magnetic Resonance on Day 3 (11.1% of patients in quercetin group vs 53.3% of patients in control group, p<0.024). There were no significant differences in left ventricle ejection fraction (LVEF) and LV remodeling indicators. Our pilot study is the first to demonstrate novel insight into ischemia/reperfusion damage in STEMI patients. The addition of quercetin to standard STEMI therapy limits infarct size and prevents intramyocardial hemorrhage after the first anterior STEMI. Further research will be necessary to both validate and expand upon these findings.

12 April 2022 in JACC: Cardiooncology
Verified
Journal Article
Open access
Sergey KozhukhovSergey Kozhukhov
Sergey Kozhukhov
NDNataliia Dovganych
Nataliia Dovganych
ISIvan Smolanka
Ivan Smolanka
IKIrina Kryachok
Irina Kryachok
OKOlexiy Kovalyov
Olexiy Kovalyov

2 August 2021 in Frontiers in Cardiovascular Medicine
Verified
Journal Article
Open access
Sergey KozhukhovSergey Kozhukhov
Sergey Kozhukhov
NDNataliia Dovganych
Nataliia Dovganych
Aim: The collaboration of cardiologists, general practitioners (GPs), and oncologists is crucial in cancer patient management. We carried out a national-based survey—The Ukrainian National Survey (UkrNatSurv)—on behalf of the Cardio-Oncology (CO) Working Group (WG) of the Ukrainian Society of Cardiology to analyze the level of knowledge in cardio-oncology.Methods: A short questionnaire was presented to specialists involved in the management of cancer patients across the country. The questionnaire was made up of eight questions concerning referred cancer patient number, CV complications of cancer therapy, diagnostic methods to detect cardiotoxicity, and drugs used for its treatment.Results: A total of 426 questionnaires of medical specialists from different regions of Ukraine were collected and analyzed; the majority of respondents were cardiologists (190), followed by GPs (177), 40 oncologists (mainly chemotherapists and hematologists), other −19 (imaging specialists, neurologists, endocrinologists, etc.). All responders were equally involved in the management of cancer patients. However, less than half of the patients have been seen before the start of cancer therapy. GPs observe the majority of patients after the end of treatment. All doctors are sufficiently aware of cancer therapy-associated CV complications. However, the necessary diagnostic tools, mostly biomarkers, are not used widely by different specialists. The criteria for cardiotoxicity, in particular, the level of reduction of the left ventricular ejection fraction (LVEF) as a marker of LV dysfunction, are not clearly understood. The specific knowledge in the management of CV complications in cancer is required.Conclusion: UkrNatSurv is the first survey in Ukraine to investigate the awareness of CO care provided to cancer patients with CV diseases (CVD) or developed CV complications. Providing such surveys among doctors involved in CO is an excellent tool to investigate the knowledge gaps in clinical practice. Therefore, the primary task is to develop a national educational CO program.

19 November 2024 in Reviews in Cardiovascular Medicine
Verified
Journal Article
Open access
PDF file
Sergey KozhukhovSergey Kozhukhov
Sergey Kozhukhov
NDNataliia Dovganych
Nataliia Dovganych
Cancer patients have an increased risk of venous thromboembolism (VTE), and VTE is the second most common cause of death among them. Anticoagulation plays a key role in the treatment of cancer-associated thrombosis (CAT). Low-molecular-weight heparin (LMWH) or direct oral anticoagulants (DOACs) are effective and generally safe options for cancer-associated VTE. However, those patients have a 10–20% risk of VTE recurrence in spite of using anticoagulants. The main reasons for recurrent VTE (rVTE) can be non-compliance, inadequate dosing of anticoagulants, thrombocytopenia and malignancy progression. Despite the publication of major guidelines regarding the management of CAT, the treatment of patients with rVTE is undefined. Treatment options for rVTE include bridging to LMWH in cases of oral anticoagulants use, LMWH dose escalation, and sometimes considering inserting a vena cava filter. This review paper summarizes the management of cancer-associated VTE, risk factors for rVTE and the treatment algorithm of rVTE.

1 January 2020 in Problems of Radiation Medicine and Radiobiology
Verified
Journal Article
Open access
Sergey KozhukhovSergey Kozhukhov
Sergey Kozhukhov
OBO. Bazyka
O. Bazyka
NDN. Dovganych
N. Dovganych
OYO. Yarynkina
O. Yarynkina
NTN. Tkhor
N. Tkhor
The review is devoted to the current issues of radiation-induced cardiovascular complications, their diagnostics and incidence depending on the radiation doses and exposure regimens, potential efficiency of the screening strategies for cardiotoxicity monitoring after radiotherapy in cancer patients by analyzing the data from literature and clinical trials, based on recommendations of European Society of Cardiology and European Society of Medical Oncology. Key words: cardiovascular complications, radiation therapy.

27 August 2020 in Ukrainian Journal of Cardiology
Verified
Journal Article
Open access
PDF file
Sergey KozhukhovSergey Kozhukhov
Sergey Kozhukhov
NDN. V. Dovganich
N. V. Dovganich
ISI. I. Smolanka
I. I. Smolanka
IKI. A. Kryachok
I. A. Kryachok
OLO. F. Ligirda
O. F. Ligirda
Cancer-associated thrombosis is an actual issue in the intersection of cardiology and oncology. Active cancer counts for approximately 20 % of the total number of cases of venous thromboembolism (VTE), and VTE is one of the leading cause of death in cancer patients, second only to cancer progression. VTE in cancer has some features that distinguish it from other VTE cases. The combination of cancer-related, treatment-related and patient-related factors increases their overall risk of VTE. The experts of the Cardio-Oncology working group have created a practical approach guideline for the management of VTE in cancer patients based on a multi-disciplinary strategy, ESMO, ASCO recommendations. This document has collected information on VTE, bleeding events and treatment modalities in cancer patients that may be beneficial for clinicians in determining strategies of anticoagulant therapies in these patients. Clinicians of various specialties using these recommendations will be able to determine the most appropriate VTE management algorithm, taking into account the bleeding risk, the type of cancer with its treatment, and drug interactions.